Waverton Investment Management Ltd cut its stake in Pfizer, Inc. (NYSE:PFE) by 8.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 440,731 shares of the biopharmaceutical company’s stock after selling 43,175 shares during the quarter. Pfizer makes up approximately 1.0% of Waverton Investment Management Ltd’s investment portfolio, making the stock its 24th largest holding. Waverton Investment Management Ltd’s holdings in Pfizer were worth $14,804,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of PFE. Asset Planning Services Ltd. raised its position in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 137 shares during the period. Orrstown Financial Services Inc. raised its position in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 612 shares during the period. Franklin Parlapiano Turner & Welch LLC bought a new position in shares of Pfizer in the first quarter valued at about $121,000. Patten Group Inc. raised its position in shares of Pfizer by 5.1% in the first quarter. Patten Group Inc. now owns 5,181 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 252 shares during the period. Finally, Kimelman & Baird LLC bought a new position in shares of Pfizer in the first quarter valued at about $203,000. 69.00% of the stock is currently owned by institutional investors.

Several equities analysts have recently weighed in on PFE shares. Credit Suisse Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $38.00 to $36.00 in a research report on Thursday, July 20th. BMO Capital Markets restated a “buy” rating and issued a $37.00 price target on shares of Pfizer in a research note on Wednesday, September 6th. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research note on Friday, July 14th. Morgan Stanley restated a “neutral” rating and issued a $35.00 price target (down from $38.00) on shares of Pfizer in a research note on Monday, June 12th. Finally, ValuEngine downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $38.04.

In other news, insider Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $34.00, for a total transaction of $249,900.00. Following the sale, the insider now directly owns 132,124 shares in the company, valued at $4,492,216. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the sale, the insider now owns 151,474 shares in the company, valued at $5,074,379. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 464,521 shares of company stock worth $15,813,961. Company insiders own 0.06% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was originally reported by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/09/25/pfizer-inc-pfe-shares-sold-by-waverton-investment-management-ltd.html.

Pfizer, Inc. (NYSE:PFE) traded down 0.33% during midday trading on Monday, hitting $35.84. 4,498,659 shares of the stock were exchanged. The company’s 50 day moving average is $33.78 and its 200 day moving average is $33.53. The company has a market capitalization of $213.15 billion, a P/E ratio of 26.22 and a beta of 1.00. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $36.21.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The firm had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same period in the prior year, the business posted $0.64 earnings per share. The company’s revenue was down 1.9% on a year-over-year basis. Analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.